StockData
Alpha Teknova, Inc. logo

Alpha Teknova, Inc. (TKNO) stock

TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30124% above fair value
$7.65−0.12 (-1.54%)

Close on Nov 17, 2026Market cap $410.72MP/E –Yield –

Alpha Teknova revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Alpha Teknova's revenue for the twelve months ending Jun 30, 2026 was $43.70M, up 12.3% year over year. For fiscal 2025 it was $40.52M, up 7.4% from the year before. The highest annual figure on record is $41.42M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$40.52M+7.4%
FY2024Dec 31, 2024$37.75M+2.9%
FY2023Dec 31, 2023$36.68M-11.4%
FY2022Dec 31, 2022$41.42M+12.3%
FY2021Dec 31, 2021$36.89M+17.9%
FY2020Dec 31, 2020$31.30M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.19M+18.5%
Q1 FY2026Mar 31, 2026$11.08M+13.1%
Q4 FY2025Dec 31, 2025$9.98M+7.8%
Q3 FY2025Sep 30, 2025$10.45M+9.2%
Q2 FY2025Jun 30, 2025$10.29M+7.0%
Q1 FY2025Mar 31, 2025$9.80M+5.4%
Q4 FY2024Dec 31, 2024$9.27M+17.8%
Q3 FY2024Sep 30, 2024$9.58M+17.2%
Q2 FY2024Jun 30, 2024$9.61M-16.6%
Q1 FY2024Mar 31, 2024$9.29M+1.9%
Q4 FY2023Dec 31, 2023$7.87M-0.3%
Q3 FY2023Sep 30, 2023$8.17M-23.6%
Q2 FY2023Jun 30, 2023$11.53M-1.4%
Q1 FY2023Mar 31, 2023$9.12M-18.2%
Q4 FY2022Dec 31, 2022$7.89M-21.9%
Q3 FY2022Sep 30, 2022$10.69M+13.8%
Q2 FY2022Jun 30, 2022$11.69M+40.6%
Q1 FY2022Mar 31, 2022$11.15M+22.8%
Q4 FY2021Dec 31, 2021$10.11M-0.5%
Q3 FY2021Sep 30, 2021$9.39M+4.5%
Q2 FY2021Jun 30, 2021$8.31M+37.5%
Q1 FY2021Mar 31, 2021$9.08M–
Q4 FY2020Dec 31, 2020$10.16M–
Q3 FY2020Sep 30, 2020$8.98M–
Q2 FY2020Jun 30, 2020$6.04M–

More Alpha Teknova figures

See a number that looks wrong?